Abbott Laboratories stock reports Q2 growth and earnings beat
📈 Abbott Laboratories beat Q2 2026 adjusted EPS expectations with a result of $1.31 versus the $1.28 consensus.
💰 Revenue surged to $12.59 billion, marking a robust 13.0% year-over-year growth for the quarter.
🚀 The company raised its full-year 2026 adjusted EPS guidance range to $5.45-$5.60 from the prior $5.38-$5.58.
📉 Stock price dipped 0.20% to close at $103.53, trading below its 52-week high of $136.83.
⚖️ Abbott agreed to a $385 million settlement regarding claims related to its 2022 powdered infant formula recall.
📊 Operating margin remained stable at 13.0%, while GAAP diluted EPS was reported at $0.53.
🎯 Comparable sales growth guidance for 2026 was retained in the range of 6.5% to 7.5%.
Bullish Signals
- Abbott Laboratories delivered a solid earnings beat with adjusted EPS of $1.31, exceeding analyst consensus by $0.03.
- The company achieved impressive revenue growth of 13.0% year-over-year, reaching $12.59 billion in Q2 2026.
- Abbott raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60, indicating strong management confidence.
- The company maintained its comparable sales growth guidance of 6.5%-7.5%, suggesting sustained market demand.
Risk Factors
- Abbott stock traded down slightly on the day, closing at $103.53 while remaining significantly below its 52-week high.
- The company faces a quantifiable legal overhang after agreeing to pay a $385 million settlement for powdered infant formula claims.
Full Analysis
Abbott Laboratories reported strong second-quarter results for 2026, posting adjusted earnings per share of $1.31 against a consensus estimate of $1.28. The company's revenue reached $12.59 billion, representing a significant year-over-year increase of 13.0%. This performance highlights the resilience of Abbott's core business segments amidst broader market conditions.
Beyond the headline numbers, the report provided updated guidance for the full fiscal year 2026. The company raised its adjusted EPS outlook to a range of $5.45 to $5.60, expanding from the previous forecast of $5.38 to $5.58. Additionally, Abbott maintained its comparable sales growth guidance between 6.5% and 7.5%, signaling confidence in sustained demand for its medical devices and diagnostics.
Despite the operational success, the stock traded down slightly on September 23, 2026, closing at $103.53. This price action reflects a market weighing the positive earnings beat against the company's distance from its 52-week high of $136.83. The valuation debate is further complicated by a recent legal settlement regarding powdered infant formula claims.
Financially, Abbott reported GAAP diluted EPS of $0.53 and net income attributable to common shareholders of $928 million for the quarter. Operating margins stood at 13.0%, indicating healthy profitability. The market capitalization was approximately $179 billion as of late September 2026, underscoring Abbott's position as a major player in the healthcare sector.
